mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

Download

 Statistics

Help

About Us
Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for FOLH1
Gene summary
Basic gene Info.Gene symbolFOLH1
Gene namefolate hydrolase (prostate-specific membrane antigen) 1
SynonymsFGCP|FOLH|GCP2|GCPII|NAALAD1|NAALAdase|PSM|PSMA|mGCP
CytomapUCSC genome browser: 11p11.2
Type of geneprotein-coding
RefGenesNM_001014986.1,
NM_001193471.1,NM_001193472.1,NM_001193473.1,NM_004476.1,
DescriptionN-acetylated alpha-linked acidic dipeptidase 1N-acetylated-alpha-linked acidic dipeptidase INAALADase Icell growth-inhibiting gene 27 proteinfolylpoly-gamma-glutamate carboxypeptidaseglutamate carboxylase IIglutamate carboxypeptidase 2glutamate car
Modification date20141222
dbXrefs MIM : 600934
HGNC : HGNC
Ensembl : ENSG00000086205
HPRD : 02961
Vega : OTTHUMG00000166625
ProteinUniProt: Q04609
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_FOLH1
BioGPS: 2346
PathwayNCI Pathway Interaction Database: FOLH1
KEGG: FOLH1
REACTOME: FOLH1
Pathway Commons: FOLH1
ContextiHOP: FOLH1
ligand binding site mutation search in PubMed: FOLH1
UCL Cancer Institute: FOLH1
Assigned class in mutLBSgeneDBB: This gene belongs to targetable_mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO IDGO TermPubMed ID


Top
Ligand binding site mutations for FOLH1
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
 : non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
G206G206RSTAD2
N544,E542T543IBLCA1
N121N121SBRCA1
E425E425VBRCA1
F565K564QCOAD1
E436E436DCOAD1
G702G702RLUAD1
R534R534ILUAD1
R511M509ILUAD1
H553H553DLUAD1
N638K637RLUAD1
G702G702RLUSC1
R511R511SLUSC1
S517S517YLUSC1
K500K500ELUSC1
N257G256RSKCM1
E486D485NSKCM1
G458G458ESKCM1
S634S634FSKCM1
N519D520YSKCM1
R210G211ESTAD1
I456I456VSTAD1
A535A535TUCEC1
Q79Q79HUCEC1
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.


Top
Protein structure related information for FOLH1
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
F565K564Q-1.14825
R511M509I-1.1059837
E436E436D-1.0698788
I456I456V-1.0655444
N544T543I-0.99901995
E542T543I-0.99901995
E486D485N-0.90828602
N121N121S-0.90024953
S517S517Y-0.83439903
H553H553D-0.80898562
G458G458E-0.77890708
R511R511S-0.76368744
E425E425V-0.71544637
R210G211E-0.6773078
G206G206R-0.66383129
R534R534I-0.42227741
Q79Q79H-0.40689645
G702G702R-0.27966195
S634S634F-0.27458727
N638K637R-0.20088952
N519D520Y-0.18740256
K500K500E-0.16784694
A535A535T-0.12401721
N257G256R-0.026331627
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for FOLH1 from PDB
PDB IDPDB titlePDB structure
1Z8LCrystal structure of prostate-specific membrane antigen, a tumor marker and peptidase

Top
Differential gene expression and gene-gene network for FOLH1
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of FOLH1 and the right PPI network was created from samples without mutations in the LBS of FOLH1. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Top

Top
Phenotype information for FOLH1
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type
umls:C0033578Prostatic Neoplasms9AlteredExpression, Biomarker

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Top
Pharmacological information for FOLH1
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
ApprovedDB00089CapromabBiotech
NutraceuticalDB00142L-Glutamic AcidSmall molecule
ExperimentalDB06928(2S)-2-{[HYDROXY(4-IODOBENZYL)PHOSPHORYL]METHYL}PENTANEDIOIC ACIDSmall molecule
ExperimentalDB07754N-({(1R)-1-carboxy-2-[(4-fluorobenzyl)sulfanyl]ethyl}carbamoyl)-L-glutamic acidSmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of FOLH1 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS
ZNZINC(2+)4ngtAE425
ZNZINC(2+)1z8lAE425 H553
ZNZINC(2+)1z8lBE425 H553
ZNZINC(2+)1z8lCE425 H553
ZNZINC(2+)1z8lDE425 H553
ZNZINC(2+)2c6cAE425 H553
ZNZINC(2+)2c6gAE425 H553
ZNZINC(2+)2c6pAE425 H553
ZNZINC(2+)2cijAE425 H553
ZNZINC(2+)2jbjAE425 H553
ZNZINC(2+)2jbkAE425 H553
ZNZINC(2+)2ootAE425 H553
ZNZINC(2+)2or4AE425 H553
ZNZINC(2+)2pvvAE425 H553
ZNZINC(2+)2pvwAE425 H553
ZNZINC(2+)2xefAE425 H553
ZNZINC(2+)2xegAE425 H553
ZNZINC(2+)2xeiAE425 H553
ZNZINC(2+)2xejAE425 H553
ZNZINC(2+)3bhxAE425 H553
ZNZINC(2+)3bi0AE425 H553
ZNZINC(2+)3bi1AE425 H553
ZNZINC(2+)3bxmAE425 H553
ZNZINC(2+)3d7dAE425 H553
ZNZINC(2+)3d7fAE425 H553
ZNZINC(2+)3d7gAE425 H553
ZNZINC(2+)3d7hAE425 H553
ZNZINC(2+)3iwwAE425 H553
ZNZINC(2+)3rbuAE425 H553
ZNZINC(2+)3sjeAE425 H553
ZNZINC(2+)3sjfAE425 H553
ZNZINC(2+)3sjgAE425 H553
ZNZINC(2+)3sjxAE425 H553
ZNZINC(2+)4jywAE425 H553
ZNZINC(2+)4jz0AE425 H553
ZNZINC(2+)4oc0AE425 H553
ZNZINC(2+)4oc1AE425 H553
ZNZINC(2+)4oc2AE425 H553
ZNZINC(2+)4oc3AE425 H553
ZNZINC(2+)4oc4AE425 H553
ZNZINC(2+)4oc5AE425 H553
ZNZINC(2+)4mcpAE425 H553
ZNZINC(2+)4mcqAE425 H553
ZNZINC(2+)4mcrAE425 H553
ZNZINC(2+)4mcsAE425 H553
ZNZINC(2+)4ngmAE425 H553
ZNZINC(2+)4ngnAE425 H553
ZNZINC(2+)4ngpAE425 H553
ZNZINC(2+)4ngqAE425 H553
ZNZINC(2+)4ngrAE425 H553
ZNZINC(2+)4ngsAE425 H553
ZNZINC(2+)4ngtAE425 H553
ZNZINC(2+)4lqgAE425 H553
ZNZINC(2+)4omeAE425 H553
ZNZINC(2+)4p44AE425 H553
ZNZINC(2+)4p45AE425 H553
ZNZINC(2+)4p4bAE425 H553
ZNZINC(2+)4p4dAE425 H553
ZNZINC(2+)4p4eAE425 H553
ZNZINC(2+)4p4fAE425 H553
ZNZINC(2+)4p4iAE425 H553
ZNZINC(2+)4p4jAE425 H553
ZNZINC(2+)4w9yAE425 H553
ZNZINC(2+)4x3rAE425 H553
PO4PHOSPHATE ION2c6pAE425 N519 H553
CACALCIUM(2+)2c6cAE436
CACALCIUM(2+)2c6gAE436
CACALCIUM(2+)2c6pAE436
CACALCIUM(2+)2cijAE436
CACALCIUM(2+)2jbjAE436
CACALCIUM(2+)2jbkAE436
CACALCIUM(2+)2ootAE436
CACALCIUM(2+)2or4AE436
CACALCIUM(2+)2pvvAE436
CACALCIUM(2+)2pvwAE436
CACALCIUM(2+)2xefAE436
CACALCIUM(2+)2xegAE436
CACALCIUM(2+)2xeiAE436
CACALCIUM(2+)2xejAE436
CACALCIUM(2+)3bhxAE436
CACALCIUM(2+)3bi0AE436
CACALCIUM(2+)3bi1AE436
CACALCIUM(2+)3bxmAE436
CACALCIUM(2+)3d7dAE436
CACALCIUM(2+)3d7fAE436
CACALCIUM(2+)3d7gAE436
CACALCIUM(2+)3d7hAE436
CACALCIUM(2+)3iwwAE436
CACALCIUM(2+)3rbuAE436
CACALCIUM(2+)3sjeAE436
CACALCIUM(2+)3sjfAE436
CACALCIUM(2+)3sjgAE436
CACALCIUM(2+)3sjxAE436
CACALCIUM(2+)4jywAE436
CACALCIUM(2+)4jz0AE436
CACALCIUM(2+)4oc0AE436
CACALCIUM(2+)4oc1AE436
CACALCIUM(2+)4oc2AE436
CACALCIUM(2+)4oc3AE436
CACALCIUM(2+)4oc4AE436
CACALCIUM(2+)4oc5AE436
CACALCIUM(2+)4mcpAE436
CACALCIUM(2+)4mcqAE436
CACALCIUM(2+)4mcrAE436
CACALCIUM(2+)4mcsAE436
CACALCIUM(2+)4ngmAE436
CACALCIUM(2+)4ngnAE436
CACALCIUM(2+)4ngpAE436
CACALCIUM(2+)4ngqAE436
CACALCIUM(2+)4ngrAE436
CACALCIUM(2+)4ngsAE436
CACALCIUM(2+)4ngtAE436
CACALCIUM(2+)4lqgAE436
CACALCIUM(2+)4omeAE436
CACALCIUM(2+)4p44AE436
CACALCIUM(2+)4p45AE436
CACALCIUM(2+)4p4bAE436
CACALCIUM(2+)4p4dAE436
CACALCIUM(2+)4p4eAE436
CACALCIUM(2+)4p4fAE436
CACALCIUM(2+)4p4iAE436
CACALCIUM(2+)4p4jAE436
CACALCIUM(2+)4w9yAE436
CACALCIUM(2+)4x3rAE436
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE2c6cAF565
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE2c6gAF565
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE2c6pAF565
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3bhxAF565
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3bi0AF565
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3bi1AF565
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3sjeAF565
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3sjgAF565
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3sjxAF565
JB7N-({(1S)-5-[ACETYL(4-BROMOBENZYL)AMINO]-1- CARBOXYPENTYL}CARBAMOYL)-L-GLUTAMIC ACID(S)-2-(3-((S)-5-(N-(4-BROMOBENZYL)ACETAMIDO)-1- CARBOXYPENTYL)UREIDO)PENTANEDIOIC ACID4ngmAG206 R210 N257 E425 N519 R534 H553
2F7N-(4-FLUOROBENZOYL)-L-ALLOISOLEUCYL-O-[(S)-{[(1S)-1,3- DICARBOXYPROPYL]AMINO}(HYDROXY)PHOSPHORYL]-L-SERINE4p44AG206 R210 N257 E425 N519 R534 H553
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE1z8lAG458 E486 F565
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE1z8lBG458 E486 F565
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE1z8lCG458 E486 F565
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE1z8lDG458 E486 F565
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE2c6cAN121
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE2c6gAN121
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3bhxAN121
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3bi0AN121
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3bi1AN121
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3bxmAN121
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3sjeAN121
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3sjgAN121
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3sjxAN121
ASPL-ASPARTIC ACID4mcsAN519 R534 H553
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3bhxAQ79
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3bi0AQ79
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3bxmAQ79
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3sjgAQ79
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3sjxAQ79
2R7N~2~-[(1-CARBOXYCYCLOPROPYL)CARBAMOYL]-N~6~-(4- IODOBENZOYL)-L-LYSINE4oc0AR210 E425 N519 R534 H553
GLUL-GLUTAMIC ACID2c6gAR210 N257 E425 H553
METMETHIONINE2cijAR210 N257 E425 H553
G88(2S)-2-(PHOSPHONOMETHYL)PENTANEDIOIC ACID3rbuAR210 N257 E425 H553
GLUL-GLUTAMIC ACID4mcsAR210 N257 E425 H553
24I2-(4-ISOBUTYLPHENYL)PROPIONIC ACID2c6cAR210 N257 E425 I456 N519 H553
T57N-{6-[(4-FLUOROBENZOYL)AMINO]HEXANOYL}-L-GAMMA- GLUTAMYL-5-{[(S)-{[(1S)-1,3- DICARBOXYPROPYL]AMINO}(HYDROXY)PHOSPHORYL]OXY}-L- NORVALINE4jywAR210 N257 E425 K500 R511 N519 E542 H553
G88(2S)-2-(PHOSPHONOMETHYL)PENTANEDIOIC ACID2jbjAR210 N257 E425 N519 H553
G88(2S)-2-(PHOSPHONOMETHYL)PENTANEDIOIC ACID2pvwAR210 N257 E425 N519 H553
2G4N-[(S)-HYDROXY(4-PHENYLBUTOXY)PHOSPHORYL]-L-GLUTAMIC ACID4p4eAR210 N257 E425 N519 H553
3K0N-SULFAMOYL-L-GLUTAMIC ACID4w9yAR210 N257 E425 N519 H553
2GBN-[(S)-(BIPHENYL-4-YLMETHOXY)(HYDROXY)PHOSPHORYL]-L- GLUTAMIC ACID4p4fAR210 N257 E425 N519 N544 H553
OKDN-({(1S)-1-CARBOXY-5-[4-(2,5,8,11,14-PENTAOXAPENTADEC-1-YL)-1H-1,2,3-TRIAZOL-1-YL]PENTYL}CARBAMOYL)-L-GLUTAMIC ACID2xejAR210 N257 E425 N519 R534 H553
BHX(2S)-2-{[(S)-(2-CARBOXYETHYL)(HYDROXY)PHOSPHORYL]METHYL}PENTANEDIOIC ACID3bhxAR210 N257 E425 N519 R534 H553
BIX(2S)-2-{[(S)-[(3S)-3-AMINO-3-CARBOXYPROPYL](HYDROXY)PHOSPHORYL]METHYL}PENTANEDIOIC ACID3bi0AR210 N257 E425 N519 R534 H553
IIIPeptide ligand (ACE,ASP,GLU)3bxmAR210 N257 E425 N519 R534 H553
FBD(S)-2-(3-((R)-1-CARBOXY-2-(4-FLUOROBENZYLTHIO)ETHYL)UREIDO)PENTANEDIOIC ACID3d7dAR210 N257 E425 N519 R534 H553
YBY(S)-2-(3-((S)-1-CARBOXY-2-(4-HYDROXY-3-IODOPHENYL)ETHYL)UREIDO)PENTANEDIOIC ACID3d7fAR210 N257 E425 N519 R534 H553
MUD(S)-2-(3-((R)-1-CARBOXY-2-METHYLTHIO)ETHYL)UREIDO)PENTANEDIOIC ACID3d7gAR210 N257 E425 N519 R534 H553
YC2(S)-2-(3-((S)-1-CARBOXY-(4-IODOBENZAMIDO)PENTYL)UREIDO)PENTANEDIOIC ACID3d7hAR210 N257 E425 N519 R534 H553
YZEN~2~-{[(1S)-1-CARBOXYBUT-3-EN-1-YL]CARBAMOYL}-N~6~-[(4-IODOPHENYL)CARBONYL]-L-LYSINE3iwwAR210 N257 E425 N519 R534 H553
SDR(2S)-2-[(N-ACETYL-L-ALPHA-ASPARTYL)AMINO]NONANOIC ACID3sjeAR210 N257 E425 N519 R534 H553
JRGN~2~-{[(1S)-1-CARBOXY-3-(METHYLSULFANYL)PROPYL]CARBAMOYL}-N~6~-(4-IODOBENZOYL)-L-LYSINE3sjfAR210 N257 E425 N519 R534 H553
T01N-(4-FLUOROBENZOYL)-L-GAMMA-GLUTAMYL-O-[(S)-{[(1S)-1,3- DICARBOXYPROPYL]AMINO}(HYDROXY)PHOSPHORYL]-L-SERINE4jz0AR210 N257 E425 N519 R534 H553
2QQN~2~-{[(1S)-1-CARBOXYBUT-3-YN-1-YL]CARBAMOYL}-N~6~-(4- IODOBENZOYL)-L-LYSINE4oc2AR210 N257 E425 N519 R534 H553
2QPN~2~-{[(1S)-1-CARBOXY-2-(FURAN-2-YL)ETHYL]CARBAMOYL}- N~6~-(4-IODOBENZOYL)-L-LYSINE4oc3AR210 N257 E425 N519 R534 H553
2QNN~2~-{[(1S)-1-CARBOXY-2-(PYRIDIN-4-YL)ETHYL]CARBAMOYL}- N~6~-(4-IODOBENZOYL)-L-LYSINE4oc4AR210 N257 E425 N519 R534 H553
2QMN~2~-{[(S)-CARBOXY(4-HYDROXYPHENYL)METHYL]CARBAMOYL}- N~6~-(4-IODOBENZOYL)-L-LYSINE4oc5AR210 N257 E425 N519 R534 H553
28ZN-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL) METHYL]AMINO}BENZOYL)-L-GAMMA-GLUTAMYL-L-GLUTAMIC ACID4mcpAR210 N257 E425 N519 R534 H553
J96N-{[(1S)-1-CARBOXY-5-({[2-({4,44-DIOXO-48-[(3AS,4S, 6AR)-2-OXOHEXAHYDRO-1H-THIENO[3,4-D]IMIDAZOL-4-YL]-7, 10,13,16,19,22,25,28,31,34,37,40-DODECAOXA-3,43- DIAZAOCTATETRACONT-1-YL}OXY)PHENYL]ACETYL}AMINO) PENTYL]CARBAMOYL}-L-GLUTAMIC ACID4ngnAR210 N257 E425 N519 R534 H553
J37N-({(1S)-6-(4-BROMOBENZYL)-1-CARBOXY-7,47-DIOXO-52- [(3AS,4S,6AR)-2-OXOHEXAHYDRO-1H-THIENO[3,4-D]IMIDAZOL- 4-YL]-10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-6, 46-DIAZADOPENTACONT-1-YL}CARBAMOYL)-L-GLUTAMIC ACID4ngqAR210 N257 E425 N519 R534 H553
J21N-{[(1S)-5-({2-[2-(ACETYLAMINO)ETHOXY]-4- BROMOBENZOYL}AMINO)-1-CARBOXYPENTYL]CARBAMOYL}-L- GLUTAMIC ACID4ngrAR210 N257 E425 N519 R534 H553
J42N-{[(1S)-5-({[4-BROMO-2-({4,44-DIOXO-48-[(3AS,4S,6AR)- 2-OXOHEXAHYDRO-1H-THIENO[3,4-D]IMIDAZOL-4-YL]-7,10,13, 16,19,22,25,28,31,34,37,40-DODECAOXA-3,43- DIAZAOCTATETRACONT-1-YL}OXY)PHENYL]CARBAMOYL}AMINO)-1- CARBOXYPENTYL]CARBAMOYL}-L-GLUTAMIC ACID4ngtAR210 N257 E425 N519 R534 H553
CTWN-(4-FLUOROBENZOYL)-L-GAMMA-GLUTAMYL-5-{[(S)-{[(1S)-1, 3-DICARBOXYPROPYL]AMINO}(HYDROXY)PHOSPHORYL]OXY}-L- NORVALINE4lqgAR210 N257 E425 N519 R534 H553
DGQDCCBL(S)-2-(3-((S)-1-CARBOXY-5-(1,2-DICARBA-CLOSO- DODECARBORANYLAMIDO) PENTYL)UREIDO)PENTANEDIOIC ACID4omeAR210 N257 E425 N519 R534 H553
2F9N-(4-FLUOROBENZOYL)-L-VALYL-O-[(S)-{[(1S)-1,3- DICARBOXYPROPYL]AMINO}(HYDROXY)PHOSPHORYL]-L-SERINE4p45AR210 N257 E425 N519 R534 H553
2G2L-GAMMA-GLUTAMYL-O-[(S)-{[(1S)-1,3- DICARBOXYPROPYL]AMINO}(HYDROXY)PHOSPHORYL]-L-SERINE4p4bAR210 N257 E425 N519 R534 H553
2GRN-[(S)-[2-(BENZOYLAMINO)ETHOXY](HYDROXY)PHOSPHORYL]-L- GLUTAMIC ACID4p4dAR210 N257 E425 N519 R534 H553
2G5N-[(S)-[(2S)-2-(BENZOYLAMINO)-2- CARBOXYETHOXY](HYDROXY)PHOSPHORYL]-L-GLUTAMIC ACID4p4iAR210 N257 E425 N519 R534 H553
2H9N-[(S)-[(2R)-2-(BENZOYLAMINO)-2- CARBOXYETHOXY](HYDROXY)PHOSPHORYL]-L-GLUTAMIC ACID4p4jAR210 N257 E425 N519 R534 H553
3BI(2S)-2-{[(R)-[(3R)-3-CARBOXY-3-{[(4-{[(2,4-DIAMINOPTERIDIN-6-YL)METHYL](METHYL)AMINO}PHENYL)CARBONYL]AMINO}PROPYL](HYDROXY)PHOSPHORYL]METHYL}PENTANEDIOIC ACID3bi1AR210 N257 E425 N519 R534 N544 H553
J31N-{[(1S)-1-CARBOXY-5-{[2-({4,44-DIOXO-48-[(3AS,4S,6AR)- 2-OXOHEXAHYDRO-1H-THIENO[3,4-D]IMIDAZOL-4-YL]-7,10,13, 16,19,22,25,28,31,34,37,40-DODECAOXA-3,43- DIAZAOCTATETRACONT-1-YL}OXY) BENZOYL]AMINO}PENTYL]CARBAMOYL}-L-GLUTAMIC ACID4ngpAR210 N257 E425 N519 R534 N544 H553
J34N-{[(1S)-1-CARBOXY-5-({[2-({4,44-DIOXO-48-[(3AS,4S, 6AR)-2-OXOHEXAHYDRO-1H-THIENO[3,4-D]IMIDAZOL-4-YL]-7, 10,13,16,19,22,25,28,31,34,37,40-DODECAOXA-3,43- DIAZAOCTATETRACONT-1-YL}OXY)PHENYL]CARBAMOYL}AMINO) PENTYL]CARBAMOYL}-L-GLUTAMIC ACID4ngsAR210 N257 E425 N519 R534 N544 H553
CI9N-({(1S)-5-[4-(13-{[2,4-BIS(DIHYDROXYAMINO)PHENYL]AMINO}-2,5,8,11-TETRAOXATRIDEC-1-YL)-1H-1,2,3-TRIAZOL-1-YL]-1-CARBOXYPENTYL}CARBAMOYL)-L-GLUTAMICACID2xegAR210 N257 E425 R511 N519 R534 E542 H553
29CN-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL) METHYL]AMINO}BENZOYL)-L-GAMMA-GLUTAMYL-L-GAMMA- GLUTAMYL-L-GLUTAMIC ACID4mcqAR210 N257 E425 R511 N519 R534 E542 H553
29DN-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL) METHYL]AMINO}BENZOYL)-L-GAMMA-GLUTAMYL-L-GAMMA- GLUTAMYL-L-GAMMA-GLUTAMYL-L-GLUTAMIC ACID4mcrAR210 N257 E425 R511 N519 R534 E542 H553
AR8N-{[(1S)-5-{4-[25-({2,4-BIS[HYDROXY(OXO)AMMONIO]PHENYL}AMINO)-2,5,8,11,14,17,20,23-OCTAOXAPENTACOS-1-YL]-1H-1,2,3-TRIAZOL-1-YL}-1-CARBOXYPENTYL]CARBAMOYL}-L-GLUTAMIC ACID2xefAR210 N257 E425 R511 N519 R534 E542 H553 G702
ARKN-({(1S)-5-[4-({2-[2-({2,4-BIS[HYDROXY(OXO)AMMONIO]PHENYL}AMINO)ETHOXY]ETHOXY}METHYL)-1H-1,2,3-TRIAZOL-1-YL]-1-CARBOXYPENTYL}CARBAMOYL)-L-GLUTAMIC ACID2xeiAR210 N257 E425 R511 N519 R534 H553
686N-({(1S)-5-[(4-BROMOBENZYL)({6-[4-(4-{4-[4-CARBOXY-3- (6-HYDROXY-3-OXO-3H-XANTHEN-9-YL)BENZOYL]PIPERAZIN-1- YL}PHENYL)PIPERAZIN-1-YL]PYRIDIN-3-YL}CARBONYL)AMINO]- 1-CARBOXYPENTYL}CARBAMOYL)-L-GLUTAMIC ACID4x3rAR210 N257 E425 R511 N519 R534 H553
QUSQUISQUALATE2jbkAR210 N257 E425 S517 H553
SDR(2S)-2-[(N-ACETYL-L-ALPHA-ASPARTYL)AMINO]NONANOIC ACID3sjgAR210 N257 E425 S517 N519 R534 H553
OSESERINE O-SULFATE2pvvAR210 N257 H553
2QS(2S)-2-[({(1S)-1-CARBOXY-2-[(2S)-OXIRAN-2- YL]ETHYL}CARBAMOYL)AMINO]-6-[(4-IODOBENZOYL) AMINO]HEXANOIC ACID (NON-PREFERRED NAME)4oc1AR210 N257 N519 R534 A535 H553
QRGN-ACETYL-L-ALPHA-ASPARTYL-L-METHIONINE3sjxAR210 N257 N519 R534 H553
QUSQUISQUALATE2or4AR210 N257 S517 H553
CLCHLORIDE2c6pAR534
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE1z8lAS634 N638
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE1z8lBS634 N638
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE1z8lCS634 N638
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE1z8lDS634 N638
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE2c6cAS634 N638
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE2c6gAS634 N638
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE2c6pAS634 N638
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3bhxAS634 N638
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3bi0AS634 N638
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3bi1AS634 N638
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3bxmAS634 N638
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3sjeAS634 N638
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3sjgAS634 N638
NAGALDEHYDO-N-ACETYL-D-GLUCOSAMINE3sjxAS634 N638


Top
Conservation information for LBS of FOLH1
Multiple alignments for Q04609 in multiple species
LBSAA sequence# speciesSpecies


Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas